Table S30: Percent of IgG+ B cells that are epitope-specific (KO-GT8++) magnitude testing between non-baseline time points for the treatment group, for frozen PBMC samples. Testing was done using Wilcoxon signed-rank test for paired data (two-sided, $\alpha = 0.05$) and p values less than 0.05 are highlighted.

	Number of Pairs	Median (Range)	P Value
20µg			
Wk4 (V06) vs. Wk8 (V07)	18	0.0528 [0.0149, 0.2292] vs. 0.0235 [0.0056, 0.1231]	<0.0001
Wk4 (V06) vs. Wk10 (V08)	17	0.0581 [0.0149, 0.2292] vs. 0.3370 [0.0889, 0.8924]	<0.0001
Wk4 (V06) vs. Wk16 (V10)	18	0.0528 [0.0149, 0.2292] vs. 0.1499 [0.0341, 0.3737]	0.0007
Wk8 (V07) vs. Wk10 (V08)	17	0.0241 [0.0056, 0.1231] vs. 0.3370 [0.0889, 0.8924]	<0.0001
Wk8 (V07) vs. Wk16 (V10)	18	0.0235 [0.0056, 0.1231] vs. 0.1499 [0.0341, 0.3737]	<0.0001
Wk10 (V08) vs. Wk16 (V10)	17	0.3370 [0.0889, 0.8924] vs. 0.1524 [0.0341, 0.3737]	<0.0001
100µg			
Wk4 (V06) vs. Wk8 (V07)	17	0.0768 [0.0241, 0.4719] vs. 0.0385 [0.0116, 0.1537]	<0.0001
Wk4 (V06) vs. Wk10 (V08)	17	0.0768 [0.0241, 0.4719] vs. 0.5124 [0.1403, 2.5581]	<0.0001
Wk4 (V06) vs. Wk16 (V10)	16	0.0789 [0.0241, 0.4719] vs. 0.2482 [0.0305, 0.8489]	0.0002
Wk8 (V07) vs. Wk10 (V08)	17	0.0385 [0.0116, 0.1537] vs. 0.5124 [0.1403, 2.5581]	<0.0001
Wk8 (V07) vs. Wk16 (V10)	16	0.0422 [0.0116, 0.1537] vs. 0.2482 [0.0305, 0.8489]	<0.0001
Wk10 (V08) vs. Wk16 (V10)	16	0.5330 [0.1403, 2.5581] vs. 0.2482 [0.0305, 0.8489]	<0.0001